ATH 11.1% 0.5¢ alterity therapeutics limited

Experimental method to study macula degeneration, page-3

  1. 2,793 Posts.
    lightbulb Created with Sketch. 970
    I missed the eye papers by Sinclair and in fact, he has 2 papers published last year. We do not know if ATH434 will activate Sirtuins but that is what I believe is happening. IMO, without sirtuin activation, the animal studies would not demonstrate so good results as we have seen in the 2 ATH434 papers published, most clearly the paper by Stefanova et al last July in the MSA animal model. As you may remember sirtuin activation needs NAD+. In the first paper below NAD+ precursor, NMN demonstrated a neuroprotective effect.

    Here are the 2 papers by Sinclair et al.

    Aging | Neuroprotective effects and mechanisms of action of nicotinamide mononucleotide (NMN) in a photoreceptor degenerative model of retinal detachment - Full Text (aging-us.com)

    Reprogramming to recover youthful epigenetic information and restore vision | Nature
 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
(20min delay)
Last
0.5¢
Change
0.001(11.1%)
Mkt cap ! $26.22M
Open High Low Value Volume
0.5¢ 0.5¢ 0.5¢ $1.913K 396.0K

Buyers (Bids)

No. Vol. Price($)
58 69165915 0.4¢
 

Sellers (Offers)

Price($) Vol. No.
0.5¢ 38302524 22
View Market Depth
Last trade - 10.34am 05/07/2024 (20 minute delay) ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.